secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001140361-25-002103
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals appoints Piratip Pratumsuwan to Board; Yalamanchi resigns
--------------------------------------------------------------------------------

- Naveen Yalamanchi resigned from Board effective Jan 25, 2025; no disagreement.
- Piratip Pratumsuwan appointed to Board effective Jan 27, 2025.
- Pratumsuwan is Managing Director, Research Analyst at RTW Investments, specializing in gene therapy.
- Received option grants: $360k (3-year monthly vest) and $155k (1-year cliff vest).
- Age 33; M.A. in Biotechnology from Columbia, B.S. in Biochemistry from McGill.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125002103/0001140361-25-002103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125002103/ef20042399_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-002103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer